Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArgenica Therapeutics Ltd

Argenica Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.095 AUD -0.01 ( 5.00%)
Last update at 2026-11-05T03:47:00Z
VOLUME
178927
Market Cap
12.20M

Momentum Score

…

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.10
Low
0.10
High
52 Week Price Range
0.09
Low
0.34
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Argenica Therapeutics Ltd is an Australia-listed life-sciences company focused on therapeutic research and development, though public disclosure on its specific programs and development stage is limited. Long-term growth drivers may include pipeline advancement, successful regulatory outcomes, and commercialization or licensing arrangements, which could support value creation for investors seeking biotech exposure.

Principal risks include clinical or regulatory failure, limited operating history and public information, funding requirements and dilution, and competitive pressures in its therapeutic area.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.10
Dividend Yield
-
Revenue TTM
5.48M
Revenue Per Share
0.04
Gross Profit TTM
5.48M
Debt / Equity
-
ROE
-20.78%
Net Debt
-6.36M
ROCE
-119.63%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -5.34M -7.17M -7.57M -4.82M -4.09M
Net income -1.37M -7.17M -5.48M -4.82M -4.09M
Selling general administrative - 0.98M 0.85M 2.25M 1.75M
Selling and marketing expenses - 1.79M 1.40M - -
Gross profit - 3.21M 2.60M - -
Ebit - - -7.57M -4.87M -4.09M
Ebitda -7.06M - -1.90M -4.81M -4.09M
Depreciation and amortization - 7.68M 5.67M - -
Operating income -7.06M -7.68M -5.67M -6.56M -4.09M
Other operating expenses 7.06M 10.90M 8.27M - 4.35M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.51M 0.19M 0.00M 0.00M
Net interest income - 0.51M 0.19M 0.06M 0.00M
Income tax expense -3.97M - -2.09M - -
Total revenue - 3.21M 2.60M 0.06M 0.00M
Total operating expenses 7.06M 10.90M 8.27M - 4.35M
Total other income expense net 1.72M 0.51M -1.90M 1.75M 0.26M
Net income from continuing ops - -7.17M -5.48M -4.82M -4.09M
Net income applicable to common shares - -7.17M -5.48M -4.82M -4.09M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6.52M 11.04M 16.38M 9.54M 9.04M
Intangible assets 0.00M 0.00M - 0.00M 0.00M
Other current assets 0.06M - 0.09M 0.05M -
Total liab 0.61M 3.80M 2.43M 1.87M 0.74M
Total stockholder equity 5.90M 7.24M 13.95M 7.67M 8.31M
Other current liab 0.19M - 1.02M 0.68M 0.06M
Common stock 29.82M - 28.43M 16.62M 13.07M
Capital stock - 29.63M - 16.62M 13.07M
Retained earnings -24.10M -22.73M -15.69M -10.32M -5.50M
Other assets - - 0.00M - -
Cash 6.36M 10.56M 15.91M 9.29M 8.91M
Total current liabilities 0.61M 3.80M 2.43M 1.87M 0.74M
Net debt -6.36M - -15.91M - -8.91M
Short term debt - - - 0.00M 0.00M
Other stockholder equity - - - 1.37M 0.75M
Total current assets 6.52M 11.04M 16.38M 9.54M 9.04M
Net tangible assets - - - 7.67M 8.31M
Short term investments - - - 0.05M -
Net receivables 0.10M - 0.37M 0.15M 0.07M
Accounts payable 0.43M 2.88M 1.40M 1.14M 0.67M
Accumulated other comprehensive income 0.18M - 1.21M - 0.75M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Long term debt total - - - 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.05M -0.05M -0.05M
Change to liabilities - - - 1.12M 0.29M
Total cashflows from investing activities - - 0.05M -0.05M -0.05M
Total cash from financing activities -0.00M 0.35M 11.63M 3.73M 5.13M
Change to operating activities - - - 0.01M 0.02M
Net income -1.37M -7.17M -5.48M -4.82M -4.09M
Change in cash -4.19M -5.36M 6.62M 0.37M 1.77M
Begin period cash flow 10.56M 15.91M 9.29M 8.91M 7.14M
End period cash flow 6.36M 10.56M 15.91M 9.29M 8.91M
Total cash from operating activities -4.19M -5.70M -5.06M -3.30M -3.36M
Issuance of capital stock - 0.35M 11.63M 3.73M 5.13M
Other cashflows from investing activities - - 0.05M -0.05M -
Change to account receivables 0.35M -0.03M -0.23M -0.07M -0.00M
Sale purchase of stock - - 11.63M 3.73M 5.13M
Other cashflows from financing activities - - 0.05M 0.00M 0.00M
Change to netincome - - - 0.46M 0.43M
Capital expenditures 4.19M 0.00M 5.06M 0.00M 0.00M
Change in working capital -2.86M -0.03M 0.28M 0.78M 0.00M
Stock based compensation - 0.11M 0.14M - -
Other non cash items 0.03M 1.38M -0.07M - -
Free cash flow - -5.70M -5.06M -3.30M -3.36M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
AGN
Argenica Therapeutics Ltd		 -0.01
5.00%		 0.10 - - 2.23 2.18 -7.28
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 -9.86

Profile*

Argenica Therapeutics Ltd

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

117 Broadway, Nedlands, WA, Australia, 6009

61 8 9329 3396

https://argenica.com.au

Name Title Year Born
Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. CEO, MD & Director NA
Dr. Samantha South GAICD, MBA, Ph.D. COO & Exec. Director NA
Ms. Emma Waldon CFO & Company Sec. 1976
Prof. Bruno Philip Meloni Chief Scientific Officer NA
Dr. Meghan Thomas Head of Clinical Devel. NA
Ms. Emma Waldon CFO & Company Secretary 1976
Ms. Emma Waldon CFO & Company Secretary 1976
Ms. Emma Waldon CFO & Company Secretary 1976
Ms. Emma Waldon CFO & Company Secretary 1976
Ms. Emma Waldon CFO & Company Secretary 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…